Catalyst

Slingshot members are tracking this event:

Seattle Genetics to report additional data from a Phase 1 trial of 33A in combination with HMAs at the European Hematology Association (EHA) annual meeting being held June 9 to 12, 2016 in Copenhagen, Denmark

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SGEN

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 11, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Hypomethylating Agents, 33a, Vadastuximab Talirin, Phase 1, Additional Data